European CHMP recommends license extension forinfliximab (Remsima)

The license extension is for the subcutaneous formulation of Remsima to include treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Source:

European Medicines Agency